On a crisp fall day, you notice the perfect maple leaf lying on the pavement. You know that you have to share this with the world, but how will you let others know how great this leaf is? After all, this leaf is awesome. In the near future, simply joining your hands in a heart […]
In a recent Globe and Mail op-ed, columnist Konrad Yakabuski argues that the likely sale and potential breakup of Blackberry would be a major setback to Canada’s innovation agenda.
A recent lawsuit filed by Myriad Genetics involving the alleged infringement of their controversial breast cancer screening tool has included the prestigious Toronto SickKids hospital as a co-plaintiff. This lawsuit has been a source of criticism for the hospital and has reinvigorated the debate on the merits of public-private research collaborations in health care innovation.
In late June, the Federal Circuit again decided Ultramercial v Hulu - a case brought by Ultramercial claiming infringement of their patent for serving online media preceded by advertising. Ultramercial's patent has been widely criticized by many commentators who view the patent as one describing an abstract concept, and believe the decision is destined for a Supreme Court appeal.
On November 24, 2011, the Federal Court of Appeal released its decision for Amazon.com, Inc. v. The Commissioner of Patents, 2011 FCA 328. This case related to patent application 2,246,933 filed by Amazon.com, Inc. entitled “Method and System For Placing A Purchase Order Via A Communications Network”. Popularly known as the “one-click shopping cart” case, […]
On June 13, 2013, the U.S. Supreme Court rendered a decision which ruled against the patenting of isolated DNA sequences in their natural form in the now infamous case involving Myriad Genetics, Inc. and the BRCA1 and BRCA2 genes. The decision represents a major milestone in the legal treatment of biotechnological inventions, and presents a number of relevant […]
Last month, the Supreme Court of Canada (SCC) denied leave to appeal in the case Eli Lilly Canada Inc v Novopharm Ltd, passing on an opportunity to clarify the controversial “promise of the patent” utility requirement for Canadian pharmaceutical patents.
Gift cards are everywhere. They are in envelopes as gifts for your friends on their birthdays. They are in your own wallet for your favourite stores. Gift cards are also in the United States Court of Appeals.
More of a cautionary winter's tale than a midsummer night's dream, an Indiana farmer facing legal action from a certain biotech and chemical multinational behemoth recently reached the U.S. Supreme Court. The case is called Bowman v. Monsanto, and with all that hangs in the balance, a herbicide-resistant rose by any other name would, in […]
The Myriad Genetics gene patenting saga has officially shaped international jurisprudence, with the Federal Court of Australia upholding the patents for BRCA1 and BRCA2. In Cancer Voices Australia v. Myriad Genetics, NSD643/2010, Federal Court of Australia (Sydney), the first Australian case to deal with the issue of gene patents, the Court took a similarly liberal […]